Daprodustat: Ph III started

GlaxoSmithKline began the open-label, U.S. Phase III ASCEND-ND trial to compare oral daprodustat once daily vs. subcutaneous darbepoetin alfa in about 4,500 non-dialysis-dependent patients switching f...